AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026)
AbCellera Biologics (ABCL) reported EBITDA Margin of 497.29% for Q1 2026, up 64181.0% on a YoY basis from N/an in Q1 2025, and down 2028.15% quarter-over-quarter from 23.37% in Q4 2025.
AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported EBITDA Margin for 7 years, with the latest figure at 497.29% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 64181.0% year-over-year to 497.29%; the trailing twelve-month figure through Mar 2026 stood at 175.97% (up 57268.0% YoY), and the FY2025 full-year result was 194.69%, up 37936.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 497.29%, down from 23.37% in the prior quarter.
- The five-year high for EBITDA Margin was 53.41% in Q1 2022, with the low at 1139.1% in Q1 2025.
- Historically, EBITDA Margin has averaged 386.09% across 5 years, with a median of 408.94% in 2024.
- The largest YoY upside for EBITDA Margin was 71636 bps in 2025 against a maximum downside of 73016 bps in 2025.
- AbCellera Biologics' EBITDA Margin stood at 141.88% in 2022, then sank by 264 bps to 516.51% in 2023, then slumped by 43 bps to 739.72% in 2024, then jumped by 97 bps to 23.37% in 2025, then tumbled by 2028 bps to 497.29% in 2026.
- The last three EBITDA Margin figures came in at 497.29% (Q1 2026), 23.37% (Q4 2025), and 638.3% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - | -497.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -497.29% |
| Dec 31, 2025 | -23.37% |
| Sep 30, 2025 | -638.30% |
| Jun 30, 2025 | -177.86% |
| Mar 31, 2025 | -1,139.10% |
| Dec 31, 2024 | -739.72% |
| Sep 30, 2024 | -772.49% |
| Jun 30, 2024 | -507.81% |
| Mar 31, 2024 | -408.94% |
| Dec 31, 2023 | -516.51% |
| Sep 30, 2023 | -426.90% |
| Jun 30, 2023 | -302.37% |
| Mar 31, 2023 | -334.15% |
| Dec 31, 2022 | -141.88% |
| Sep 30, 2022 | 24.99% |
| Jun 30, 2022 | -15.24% |
| Mar 31, 2022 | 53.41% |
| Dec 31, 2021 | 42.76% |
| Sep 30, 2021 | -415.54% |
| Jun 30, 2021 | -0.62% |